Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC1R | Q01726 | 8/20 | 0.73 |
| ▸ | MC4R | P32245 | 8/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16188227 | 0.87 | MC1R (0.72) | MC1RMC4RKMT2AP2RY12 | |
| SCHEMBL16444996 | 0.86 | MC1R (0.70) | MC1RMC4RKMT2AP2RY12 | |
| SCHEMBL20450385 | 0.85 | MC1R (1.00) | MC1RMC4RP2RY12 | |
| SCHEMBL16445574 | 0.85 | MC1R (0.61) | MC1RMC4RMEN1KMT2AP2RY12 | |
| SCHEMBL2149032 | 0.85 | MC1R (0.62) | MC1RMC4RGAAMAPTAPP | |
| Trifluoroacetic Acid SCHEMBL1311384 | 0.84 | MC1R (0.58) | MC1RMC4RPOLB | |
| SCHEMBL1311665 | 0.83 | MC1R (0.58) | MC1RMC4RGAAMAPTAPP | |
| Trifluoroacetic Acid SCHEMBL1310554 | 0.83 | MC1R (0.92) | MC1RMC4RTACR1P2RY12 | |
| SCHEMBL16445371 | 0.81 | MC1R (0.62) | MC1RMC4RGAAKMT2A | |
| SCHEMBL14360222 | 0.80 | MC1R (0.61) | MC1RMC4RTACR1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342194-B1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2018-08-08 | — | — | EP | disclosed |
| US-9630949-B2 | Oxoazetidine derivatives, process for the preparation thereof and use thereof in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-04-25 | — | — | US | disclosed |
| US-20150045559-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045559-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | CYP51A1, TYR, CYP2C19 | MC1R 195/4885MC4R 873/4885GAA 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.